TO THE EDITOR-We read the article by Seto et al [1] with interest. The authors investigated the correlation of HLA-DP and interleukin 28B (IL-28B) polymorphisms with hepatitis B surface antigen (HBsAg) seroclearance in hepatitis B virus (HBV) patients, and found that IL-28B haplotype CG (rs12979860/rs8099917) was associated with HBsAg clearance. The role of IL-28B polymorphisms in HBV has been increasingly explored, but till now only conflicting results have been achieved.
Recently we reviewed current studies delving into IL-28B and spontaneous HBV clearance and searched databases including PubMed, Embase, Web of Science, and Chinese National Knowledge Infrastructure using the terms interleukin 28B and hepatitis B through 1 March 2013. In total, 145 articles were searched. After preliminary screening, 9 articles in English and 1 in Chinese investigating the association between IL-28B and HBV seroclearance were encompassed. Among them, 1 article obscured the genotype distributions and was omitted from our analysis [2] , and 1 with virus clearance after interferon treatment was excluded [3] as well. Therefore, 8 studies in which genotype distributions of IL-28B were shown or could be figured out were included ultimately (7 studies involving rs12979860, 3 involving rs8099917, and 2 involving rs12980275, most of which were conducted in Asians; see Supplementary  Table 1 ). We analyzed the correlation between IL-28B polymorphisms and HBV seroclearance through meta-analysis in a recessive model and allele model. For rs8099917, only 3 studies presented the genotype distributions and thus were finally selected, including 487 patients and 389 controls. No significant relationship between IL-28B and virus clearance was observed (recessive model: OR = 1.084, 95% CI, .722-1.629, P = .696; allele T > G: OR = 1.092, 95% CI, .753-1.585, P = .643). Additionally, we analyzed rs12980275 as well, but only to find insignificant results (recessive model: OR = 0.949, 95% CI, .556-1.618, P = .847; allele A > G: OR = 0.956, 95% CI, .584-1.564, P = .857) ( Table 1) .
Therefore, confirmative evidence to support that IL-28B polymorphisms correlate with virus clearance in HBV patients is lacking, although the correlation has been exemplified in HCV patients. Seto et al [1] found that IL-28B haplotype CG correlated with HBsAg seroclearance and considered IL-28B to be pertinent to virus eradication, but the frequencies of haplotype CG in both case and control groups were <0.03 (0.025 and 0.002, respectively). Such a low frequency would spark concern on its clinical influence on the seroclearance of HBsAg as few people have such genetic background. Additionally, Lampertico et al [3] and Sonneveld et al [4] corroborated the association with seroclearance after interferon treatment, whereas Martin et al [5] found no correlation with spontaneous clearance in white individuals. Besides, most of the studies included in the meta-analysis were conducted in Asians and no remarkable correlation was observed. Therefore, IL-28B polymorphisms did not correlate with spontaneous seroclearance of HBV, irrespective of race, but might associate with treatment response after administering interferon.
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